
Eli Lilly (LLY) is back in focus after the U.S. Food and Drug Administration granted full approval for Inluriyo, used with Verzenio in certain ESR1 mutated metastatic breast cancer patients. Eli Lilly’s share price has eased over the past month, with a 30-day share price return of 8.16% in the red. However, the 1-year total shareholder return of 53.68% and roughly 4x gain over five years point to momentum that remains firmly intact. Compare Eli Lilly’s oncology and obesity story with other...



























